Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: R. M. Rosenthal who wrote (578)	12/11/1997 1:04:00 AM
From: Gurupup	Respond to of 5736

Please use this as a start and go back and read Janybirds past posts. You all are asking questions which have been answered too many times in the past. Janybird is an investor, not a slave to people that are too lazy to go back and read the marvelous job that she has done. She is too much of a lady to tell you to do your own homework, and it is ALL on this board. Pleae give her a break, as the more repetitive questions you have, the less real work that can be done on this board. GO BACK AND READ IT IS ALL THERE. Subject: Chromatics Color Sciences International. Inc; CCSI \| Previous \| Next \| Respond \| Show Navigation To: +Richard N Lambert (297 ) From: +Janybird Monday, Sep 15 1997 8:52PM EST Reply # of 578 Size of Market News ________________________________________________________________________________________ Chromatics Announces Analysis of Existing Market for Newborn Bilirubin Testing ________________________________________________________________________________________ Chromatics Color Sciences International Inc. today announced that it has completed its analysis of the existing market for bilirubin tests on newborn infants in the United States, and the approximate size of that market in the developed countries of Europe, South America and Canada combined, and Asia. The World Health Organization has published the current annual birthrate of approximately 4,000,000 births in the United States, with approximately 10 percent of these births being premature infants. The company estimates that individual bilirubin blood tests on newborn infants (heelsticks), which are not part of a general panel blood test, total approximately 15,000,000 tests performed annually in the United States, based on data made available by the World Health Organization, the American Academy of Pediatrics, independent market studies commissioned by the company and business proposals from potential marketing partners. The company believes that published reimbursement amounts by third party insurance carriers for heelstick bilirubin blood tests, not part of a panel test, range between $22-$34 per test in the United States. Assuming a $22 fee, the company estimates that approximately $330 million is spent annually on monitoring bilirubin infant jaundice in the United States. Internationally, using the World Health Organization birth rates, independent market studies and research obtained from companies currently marketing neonatal medical devices in foreign countries, the company estimates that the current European market for infant bilirubin tests is approximately the same size as the U.S.; South America and Canada combined represent approximately 25 percent of the U.S. market size and the Southern Chinese and entire Japanese markets combined represent approximately the same size of market as the United States. Since recently receiving FDA marketing clearance in the U.S., the company is currently undertaking the procedures to obtain required international regulatory clearances for its noninvasive bilirubin monitoring device and technology. The company has also begun the process of establishing third party reimbursement for its noninvasive bilirubin testing which will be an important factor in its pricing structure in the United States. Based on the company's initial business discussions with International Medical Device Companies interested in global distribution rights for the company's noninvasive bilirubin monitoring medical device for newborns, significant market penetration in the U.S. and International markets would require 3-4 years from the start of commercial distribution. The company also stated that it could not at this time disclose the pricing structure and business models currently being discussed with different potential distribution partners, including any increased market potential for noninvasive testing. In this regard, the company has recently retained the services of two business advisors to assist in current discussions, analysis and execution of its long range marketing and distribution plan. The company is engaged in the business of color science and has developed technologies with potential medical applications involving the detection and monitoring of certain chromogenic diseases. These technologies also have other applications including the scientific color measurement and classification of human skin, certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the cosmetic, beauty aid and fashion industries. The company's common stock and warrants are traded on NASDAQ under the symbols''CCSI'' and ''CCSIW'' respectively. Forward looking statement......... \| Previous \| Next \| Respond \| View SubjectMarks Bookmark this Subject Return to Medical Devices One or more words separated by spaces: Subject Titles Only Full-Text Messages with Links Send questions and feedback to webmistress@techstocks.com Terms of Use

To: R. M. Rosenthal who wrote (578)	12/11/1997 1:07:00 AM
From: Gurupup	Read Replies (1) \| Respond to of 5736

Go back to company's release on 9/17, and this will answer all of your questions. If you want continuing work, do some yourselves, please. Much work and effort has gone into this board, and you now have to do your own, or you shouldn't be here, or in the stock. Don't waste time flaming me, I am thin-skinned, stubborn,obstinate, opinionated, irrascible, and fed up with questions that have been answered many times. I beat my wife, kick my dogs, and hate laziness.